Close
Solutions
Online Inquiry
Global Services

CellRapeutics™ Cytokine Release Test

All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.

Why Monitoring Cytokines In CAR-T Therapy

Cytokines are an important player in the context of CAR-T cell therapy for cancer. When CAR-T cells encounter cancer cells expressing the target antigen, CAR-T cells are activated and can secrete large amounts of cytokines as part of the immune response. However, excessive and uncontrolled cytokine release can lead to severe adverse reactions known as cytokine release syndrome (CRS). After the infusion of CAR-T cells, patients potentially experience CRS. Therefore, the cytokine release test is a necessary step to ensure the safety and efficacy of the final product and provides valuable insights into the immune response generated by the CAR-T treatment. Creative Biolabs provides various cytokine release test services, such as ELISA-based cytokine detection using highly sensitive antibodies to ensure accurate and reliable results.

Fig.1 CAR-T therapy and CRS. (Cosenza, et al., 2019) Fig.1 CAR-T therapy and CRS.1

Our Services

  • Various Cytokine Release Assays
    At Creative Biolabs, we provide various assays to measure cytokine production during the development of CAR-T cell therapy products. Our techniques including ELISA, ELISPOT, and multiplex bead array are used for the quantitative measurement of cytokines in serum, plasma, tissue culture supernatants, and other biological fluids. These techniques have been extensively used in basic research and clinical trials to assess the levels of cytokines in CAR-T cell therapy.
    • ELISA allows for the quantitative measurement of cytokines in various biological samples.
    • ELISPOT allows for the detection of individual cytokine-producing cells.
    • Multiplex bead array allows for the simultaneous measurement of multiple cytokines in a single sample.

Please get in touch with us for more details.

  • Detection of Various Cytokines

We offer multiple cytokines release assays to evaluate the release of various cytokines, including but not limited to:

TNF-α IFN-γ IL-2 IL-4 IL-6 IL-7 IL-8
IL-10 IL-12 IL-13 Granzyme GM-CSF MIP-1α

Advantages

  • High sensitivity: Our assays can detect cytokines at very low concentrations, allowing us to detect small changes in cytokine levels.
  • Standardized protocols: We use standardized protocols for all our assays, ensuring consistent and reliable results.
  • Expertise: Our team of experts has extensive experience in cytokine detection and CAR-T cell therapy product development, ensuring that we provide the best possible service to our clients.

Support Data

Here are some representative data for CAR-T cell cytokine release assays.

Case 1: Analysis of cytokine release by bead-based immunoassay.

Fig.2 Analysis of cytokine levels in plasma of CAR T cells. (Lee, et al., 2019) Fig.2 Analysis of cytokine levels in plasma of CAR T cells.2

Case 2: Analysis of cytokine release by ELISA.

Fig.3 Analysis of cytokine release of anti-hGPC3 CAR-T cells in supernatants. (Liu, et al., 2020) Fig.3 Analysis of cytokine release of anti-hGPC3 CAR-T cells in supernatants.3

Case 2: Analysis of cytokine release by ELISPOT.

Fig.4 ELISPOT assay for detection of IFN-γ release by anti-CEA CAR-T cells. (Elkord, et al., 2021) Fig.4 ELISPOT assay for detection of IFN-γ release by anti-CEA CAR-T cells.4

References

  1. Cosenza, Maria, Stefano Sacchi, and Samantha Pozzi. "Cytokine release syndrome associated with T-cell-based therapies for hematological malignancies: pathophysiology, clinical presentation, and treatment." International Journal of Molecular Sciences 22.14 (2021): 7652.
  2. Lee, Yong Gu, et al. "Regulation of CAR T cell-mediated cytokine release syndrome-like toxicity using low molecular weight adapters." Nature communications 10.1 (2019): 2681.
  3. Liu, Xuan, et al. "Split chimeric antigen receptor-modified T cells targeting glypican-3 suppress hepatocellular carcinoma growth with reduced cytokine release." Therapeutic advances in medical oncology 12 (2020): 1758835920910347.
  4. Elkord, E., and D. J. Burtà. "Novel IFNc ELISPOT Assay for Detection of Functional Carcinoembryonic Antigen-Specific Chimeric Antigen Receptor-Redirected T Cells." Scandinavian Journal of Immunology 74 (2011): 419–422
Online Inquiry

For any technical issues or product/service related questions, please leave your information below. Our team will contact you soon.

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Key Updates
Newsletter NEWSLETTER

The latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders

LEARN MORE NEWSLETTER
New Solution NEW SOLUTION

CellRapeutics™ In Vivo Cell Engineering: One-stop in vivo T/B/NK cell and macrophage engineering services covering vectors construction to function verification.

LEARN MORE SOLUTION
NOVEL SOLUTION NOVEL TECHNOLOGY

Silence™ CAR-T Cell: A novel platform to enhance CAR-T cell immunotherapy by combining RNAi technology to suppress genes that may impede CAR functionality.

LEARN MORE NOVEL TECHNOLOGY
NEW TECHNOLOGY NEW SOLUTION

Canine CAR-T Therapy Development: From early target discovery, CAR design and construction, cell culture, and transfection, to in vitro and in vivo function validation.

LEARN MORE SOLUTION
Receive our latest news and insights.